NCT05035056Completed
WARRIOR Ancillary Study for CCTA Analysis
Effect of Intensive Medical Treatment on Quantified Coronary Artery Plaque Components With Serial Coronary CTA in Women With NonObstructive CAD
Source: ClinicalTrials.gov · Last updated 19 Mar 2026
Brief summary (registry, in English)
In this study, quantitative characterization of plaque using coronary computed tomographic angiography (CTA) will be used to determine if women who were treated with intensive medical therapy have a greater reduction in the amount and type of cholesterol plaque compared to women receiving usual care and if this results in beneficial changes in clinical symptoms. The study will provide an understanding of how intensive medical therapy works in providing clinical benefit in women with nonobstructive plaque.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 191 (actual)
- First submitted
- 20 Aug 2021
- Start date
- 1 Jul 2020
- Primary completion date
- 2 May 2025
- Lead sponsor
- Cedars-Sinai Medical Center
- Diseases
- Coronary artery disease
- NCT number
- NCT05035056
What you commit to
- Study type: Observational
- Participants enrolled: 191
- From 1 Jul 2020 to the primary completion date, 2 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- In addition to exclusion criteria of the parent WARRIOR trial, key exclusion criteria are:
- Non-adherent with IMT. The parent trial is already powered for non-adherence. In our ancillary trial we have built in an exclusion, from final analysis, of an additional 30% who may be nonadherent with IMT or UC.
Who the study is looking for
- In addition to the inclusion criteria of the WARRIOR trial, only women who meet the following criteria will undergo final CTA at the same sites where they are screened and enrolled.
- Initial CTA with excellent or good image quality-defined as images where we are able to clearly identify the atherosclerotic plaque. Based on our preliminary assessment, we expect 90% of studies to be included.
- Measurable plaque with total plaque volume \>0mm3; women without significant plaque will not receive additional radiation, and we can detect measurable changes in plaque burden and plaque composition.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cedars-Sinai Medical Center Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
Related publications
- Design and rationale of the WARRIOR ancillary study for coronary CT angiographic analysis.Am Heart J · 2026 · PMID 41485680
This page is information, not medical advice. Discuss any trial with your doctor.